Search
Filter Results
Displaying 21–30 of 52 for “Vitamin A”
-
Oct 10, 2022
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Reports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
Nov 8, 2021
Foundation Insights Forum – October 28, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on October 28, 2021.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
-
Sep 27, 2021
Foundation Awarded 21 New Grants in FY2021 Totaling More than $14.2 Million
Current research portfolio is comprised of nearly 100 projects at prominent institutions around the world
-
Aug 18, 2021
Foundation Insights Forum – August 12, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on August 12, 2021.
-
Feb 3, 2021
Foundation Insights Forum – January 29, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 29, 2021.
-
Full Transcript - 2019 Investing in Cures Summit - March 2, 2019
Full Session Transcripts of the 2019 Investing in Cures Summit.
-
Nov 21, 2018
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
The Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
Age-Related Macular Degeneration
Age-related macular degeneration, or AMD, is the leading cause of blindness in people 55 and older in developed countries. The condition can lead to significant loss of central vision.